title: The potential of targeting Ras proteins in lung cancer.
abstract: The Ras pathway is a major driver in lung adenocarcinoma: over 75% of all cases harbor mutations that activate this pathway. While spectacular clinical successes have been achieved by targeting activated receptor tyrosine kinases in this pathway, little, if any, significant progress has been achieved targeting Ras proteins themselves or cancers driven by oncogenic Ras mutants. New approaches to drug discovery, new insights into Ras function, new ways of attacking undruggable proteins through RNA interference and new ways of harnessing the immune system could change this landscape in the relatively near future.
authors.affiliation: University of California, Helen Diller Family Comprehensive Cancer Center , 1450 3rd St, Box 0128, San Francisco, CA 94158-9001 , USA mccormic@cc.ucsf.edu.
authors.forename: Frank
authors.initials: F
authors.lastname: McCormick
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D034622:RNA Interference; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D018631:ras Proteins
keywords: Ras; adenocarcinoma; drug discovery; targeting proteins